Drug Trial Radar · NCT05866809
Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Oct 28, 2021
Primary completion
Jun 23, 2023
Study completion Jul 24, 2023
Sponsor
- Lead sponsor
- CuromeBiosciencesIndustry
- Sponsor type
- Industry
- First posted
- May 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC). Percentage of subjects who show improvement of severity of PSC as assessed by Magnetic Resonance Cholangiopancreatography(MRCP) at Week 12 from baseline, with improvement defined as a decrease of -1 or more in the MRCP and change of alkaline phosphatase(ALP) level will be assessed at Week 12 from baseline.
Conditions
- Primary Sclerosing Cholangitis
Interventions
HK-660SDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRCPTime frame: Week 12 from baseline
- ALPTime frame: Week 12 from baseline
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
ASAN Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.